[1] 郑振东, 韩涛.胃癌诊疗研究进展[J].临床军医杂志, 2017, 45(1):1-4. [2] 左婷婷, 郑荣寿, 曾红梅, 等. 中国胃癌流行病学现状[J]. 中国肿瘤临床, 2017, 44(1):52-58. [3] TAHARA T, ARISAWA T. DNA methylation as a molecular biomarker in gastric cancer[J]. Epigenomics, 2015, 7(3):475-486. [4] WU G Z, CAI J, HAN Y, et al. LincRNA-p21 regulates neointima formation, vascular smooth muscle cell proliferation, apoptosis, and atherosclerosis by enhancing p53 activity[J]. Circulation, 2014, 130(17):1452-1465. [5] 徐艳雪, 朱友明, 陈乔尔. p53相关长链非编码RNA在肿瘤发生发展中作用的研究[J]. 安徽医药, 2018, 22(7):1230-1235. [6] WANG X H, RUAN Y, WANG X J, et al. Long intragenic non-coding RNA lincRNA-p21 suppresses development of human prostate cancer[J]. Cell Prolif, 2017, 50(2):e12318. [7] 于景霞, 刘婷, 李沁恺, 等. 特异性抑制JAK/STAT3信号通路对大鼠肝细胞癌的影响[J]. 胃肠病学, 2017, 22(5):272-275. [8] ZHANG W Y, DONG R, DIAO S, et al. Differential long noncoding RNA/mRNA expression profiling and functional network analysis during osteogenic differentiation of human bone marrow mesenchymal stem cells[J]. Stem Cell Res Ther, 2017, 8(1):30. [9] 朱银银, 艾合麦提江·库尔班, 沈钲杰, 等. 胃癌中长非编码RNA调节网络的研究进展[J]. 中国细胞生物学学报, 2017, 39(10):1369-1373. [10] 章华丽, 蔡希, 赵素凡, 等. 非胃肠道表现为首发症状的胃癌危险因素及预后分析[J]. 中国预防医学杂志, 2018, 19(6):432-436. [11] 田智, 刘亮华, 廖江涛. 长链非编码核糖核酸Malat-1、p21和GAS5在大肠癌组织中的表达及其诊断价值[J]. 华中科技大学学报(医学版), 2017, 46(1):10-14. [12] LU M Y, LIAO Y W, CHEN P Y, et al. Targeting LncRNA HOTAIR suppresses cancer stemness and metastasis in oral carcinomas stem cells through modulation of EMT[J]. Oncotarget, 2017, 8(58):98542-98552. [13] PAN Y Y, PAN Y Q, CHENG Y, et al. Knockdown of LncRNA MAPT-AS1 inhibites proliferation and migration and sensitizes cancer cells to paclitaxel by regulating MAPT expression in ER-negative breast cancers[J]. Cell Biosci, 2018, 8:7. [14] SHI J G, ZHANG W, TIAN H Y, et al. lncRNA ROR promotes the proliferation of renal cancer and is negatively associated with favorable prognosis[J]. Mol Med Rep, 2017, 16(6):9561-9566. [15] SONG P, JIANG B, LIU Z J, et al. A three-lncRNA expression signature associated with the prognosis of gastric cancer patients[J]. Cancer Med, 2017, 6(6):1154-1164. [16] PENCIK J, PHAM H T, SCHMOELLERL J, et al. JAK-STAT signaling in cancer:from cytokines to non-coding genome[J]. Cytokine, 2016, 87:26-36. [17] KHANNA P, CHUA P J, BAY B H, et al. The JAK/STAT signaling cascade in gastric carcinoma (Review)[J]. Int J Oncol, 2015, 47(5):1617-1626. [18] BI C L, ZHANG Y Q, LI B, et al. MicroRNA-520a-3p suppresses epithelial-mesenchymal transition,invasion, and migration of papillary thyroid carcinoma cells via the JAK1-mediated JAK/STAT signaling pathway[J]. J Cell Physiol, 2019, 234(4):4054-4067. [19] OLSON T L, LOUGHRAN T P Jr. Restoring the long noncoding RNA MEG3 indicates a potential role for JAK-STAT signaling in chronic myeloid leukemia[J]. EBioMedicine, 2018,35:24. [20] GONG W, QIE S, HUANG P, et al. Deletion of long noncoding RNA EFNA3 aggravates hypoxia-induced injury in PC-12 cells by upregulation of miR-101a[J]. J Cell Biochem, 2019, 120(1):836-847. |